Zacks Research Has Bearish Estimate for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for Bruker in a report released on Monday, February 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $0.83 per share for the quarter, down from their prior forecast of $0.86. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company reduced their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Bank of America boosted their price objective on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. UBS Group started coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Finally, The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a report on Thursday, December 5th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $74.09.

Bruker Trading Up 2.0 %

BRKR stock opened at $51.65 on Thursday. Bruker has a one year low of $48.07 and a one year high of $94.86. The stock has a market cap of $7.83 billion, a price-to-earnings ratio of 24.83, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The company has a fifty day moving average price of $57.88 and a two-hundred day moving average price of $60.77. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Several large investors have recently bought and sold shares of the business. True Wealth Design LLC lifted its holdings in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares during the last quarter. Eagle Bay Advisors LLC boosted its position in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after buying an additional 674 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Bruker during the 3rd quarter valued at $73,000. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.